Skip to main content
Michael Press, MD, Pathology, Los Angeles, CA, Keck Hospital of USC

MichaelFPressMD

Pathology Los Angeles, CA

Anatomic Pathology, Clinical Pathology

Professor, Pathology, USC School of Medicine

Dr. Press is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Press' full profile

Already have an account?

Education & Training

  • University of Chicago
    University of ChicagoResidency, Pathology-Anatomic and Clinical, 1977 - 1981
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1977
  • University of Chicago
    University of ChicagoPh.D., Cell Biology , 1970 - 1975

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1978 - 2026
  • FL State Medical License
    FL State Medical License 2015 - 2026
  • NV State Medical License
    NV State Medical License 2012 - 2025
  • CA State Medical License
    CA State Medical License 1988 - 2024
  • NC State Medical License
    NC State Medical License 2015 - 2024
  • ID State Medical License
    ID State Medical License 2012 - 2022
  • American Board of Pathology Anatomic Pathology

Publications & Presentations

PubMed

Journal Articles

  • RNA-Seq of Circulating Tumor Cells in Stage II–III Breast Cancer  
    Michael F Press, Julie E Lang, Annals of Surgical Oncology

Abstracts/Posters

  • Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
    Michael Press, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • AR Emerges as a Potential Target in Triple-Negative Breast Cancer
    AR Emerges as a Potential Target in Triple-Negative Breast CancerMarch 24th, 2017
  • HER2 Gene Testing Guidelines May Misclassify Patients
    HER2 Gene Testing Guidelines May Misclassify PatientsMarch 13th, 2017
  • Expert Sheds Light on Issues with ASCO-CAP HER2 Guidelines
    Expert Sheds Light on Issues with ASCO-CAP HER2 GuidelinesSeptember 27th, 2016
  • Join now to see all

Grant Support

  • Pathobiology Of Breast Cancer And Hormone ReceptorsNational Cancer Institute1988–2003
  • Pilot--Breast CancerNational Cancer Institute2001–2002
  • HER-2 NEU Proto-Oncogene In Ovarian &Endometrial CancerNational Cancer Institute1991–1993

Hospital Affiliations